title: Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
authors.forename: M Christina
authors.initials: MC
authors.lastname: Cox
authors.forename: Massimo
authors.initials: M
authors.lastname: Marignani
authors.forename: Barbara
authors.initials: B
authors.lastname: Veggia
authors.forename: Stefano
authors.initials: S
authors.lastname: Angeletti
authors.forename: Francesco
authors.initials: F
authors.lastname: Leone
authors.forename: Paola
authors.initials: P
authors.lastname: Cipriani
authors.forename: Sara
authors.initials: S
authors.lastname: Gallina
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Delle Fave
authors.forename: M Antonietta
authors.initials: MA
authors.lastname: Aloe-Spiriti
authors.forename: Bruno
authors.initials: B
authors.lastname: Monarca
mesh_terms: D002755:Choice Behavior; D019468:Disease Management; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*
chemical_list: D019259:Lamivudine